ICH Guidelines for Shelf Life of Pharmaceuticals

Overview:

The objective of estimating the shelf life of a product is to determine the duration of storage within which the entire product will meet the required specifications with a sufficiently high probability. Ensuring the estimated shelf life is applicable to all future batches is of utmost importance, as emphasized in the International Conference on Harmonization (ICH) guidelines (ICH Q1E, International Conference on Harmonization, 2003b). However, certain concerns have arisen regarding the efficacy of these guidelines in accurately estimating shelf life.

The ICH guidelines have been criticized for several issues, including the consideration of fixed batch effects, the requirement for pool ability tests, and the determination of confidence intervals for the mean. To address these concerns, two key conclusions can be drawn from evaluating the ICH procedure. Firstly, it is essential to consider batch effects as random rather than fixed, ensuring a more accurate representation of real-world scenarios. Secondly, the focus should shift towards estimating a quantile, which provides valuable information regarding the shelf life (minimum).

In order to overcome these limitations, a new procedure is required that combines the concept of random batch effects with the ICH's objective of estimating the batch shelf life (minimum). By incorporating these improvements, the estimation of shelf life can be enhanced, enabling more reliable and robust assessments for future product batches.

What Is ICH?

The aim of the International Conference on Harmonization (ICH) document is to provide guidance regarding the essential information that should be included in a core clinical study report for any human study involving therapeutic, prophylactic, or diagnostic agents.

By adhering to this guideline, sponsors can ensure that the clinical study report contains all necessary details, leaving no room for ambiguity. It emphasizes the importance of completeness, ensuring that all relevant information is included to provide a thorough understanding of the study and its outcomes. The guideline also emphasizes the need for an organized presentation of data, making it easier for regulatory authorities and other stakeholders to review and assess the study report effectively.

ICH document provides valuable recommendations for sponsors to create high-quality clinical study reports. By following these guidelines, sponsors can enhance the transparency, accuracy, and comprehensiveness of their reports, facilitating the regulatory review process and contributing to the overall integrity of clinical research.

How to Determine the Shelf Life of Pharmaceuticals?

Shelf life guidelines provide guidance on how to determine and declare the product's expiration date or shelf life based on stability testing data. The guidelines set by regulatory authorities often incorporate the principles outlined by ICH to ensure consistency and harmonization in determining the shelf life of pharmaceutical products.

Expiration Date Testing

• Absence of an Expiration Date: According to 21 CFR 211.137, all drug products that have been packaged after September 29, 1979, are mandated to display an expiration date. Failure to comply with this requirement may result in regulatory action being taken against the product and/or the responsible company.

• Exemptions: However, there are exemptions outlined in 211.137 (g) for certain over-the-counter (OTC) drug products. These exempted OTC products can utilize accelerated testing programs to demonstrate stability for a minimum of three years. Additionally, information obtained from old stock, which has not been previously subjected to stability studies, may be utilized to support the expiration date.

• Products Reconstituted for Reconstruction: For drug products intended for reconstitution, it is necessary to have separate expiration dates for the un-reconstituted product and the product after reconstitution. Failure to provide separate expiration dates for each form of the product would be considered non-compliant with 211.137 (c). Separate stability studies must be conducted to support each expiration date for these products.

Stability Testing

• Written Stability Testing Program:

  • According to the regulations, the absence of a written protocol for stability testing can lead to regulatory action against the product and/or the responsible firm.

• Supportive Stability Data:

  • Number and Size of Batches: For the purpose of establishing an expiration date, it is permissible to conduct initial stability testing on a smaller batch size, provided that the batch is manufactured using equipment similar to that used in regular production. Ongoing stability studies should also involve a portion of the annual production batches to account for any variables inherent in the production process.

  • Accelerated Studies: Accelerated stability studies can be performed using one batch to establish a tentative expiration date. However, it is discouraged to rely solely on accelerated data to establish an expiration dating period of more than three years. Combining data from room temperature and accelerated temperature testing can be used to justify an expiration date of over two years.

  • Test Intervals: It is generally advised to initiate stability testing initially, followed by testing every three months during the first year, every six months during the second year, and subsequently once a year. However, it is essential to perform at least one stability test annually to meet compliance requirements. Some companies may opt to conduct stability tests on random dates as long as at least one test is performed each year. When storing the product under controlled conditions, it is important to record the specific storage conditions, including temperature and humidity.

  • Storage Conditions: When storing a product under controlled conditions, it is essential to accurately record the specific storage conditions, including temperature and humidity. Simply stating "room temperature" is insufficient to ensure proper storage. Controlled room temperature is defined as a range between 15 and 30 degrees Celsius (59 and 86 degrees Fahrenheit). For products that are susceptible to degradation by light or moisture, it is important to replicate the conditions of use or even exaggerate them during storage. For instance, if a product is sensitive to light, it may not be necessary to store it in a well-lit area if it is packaged in an opaque container that provides adequate protection against light exposure. Consideration should be given to the specific vulnerabilities of the product, and appropriate measures should be taken to preserve its stability.

  • Test Methods: The test methods utilized in stability testing must demonstrate reliability, significance, specificity, and accuracy. Verification of testing methods should be conducted under actual conditions of use to ensure their suitability and effectiveness. Stability testing should incorporate stability-indicating tests that can differentiate the active ingredient from degradation products and provide an estimation of their quantities. It is important to note that the stability-indicating test does not necessarily have to be identical to the assay method used for determining product strength. The focus should be on employing appropriate tests that specifically detect changes in the active ingredient and related degradation products.

  • Container-Closure Systems: Stability testing should generally be performed in the same container-closure system as the marketed drug product. However, repackaging into alternative systems may be allowed if it can be demonstrated that the new system provides equal or better protection than the original system. Comparisons can be made through permeation testing, stress testing, or literature references. Repackaging solid dosage units from plastic to glass containers may be acceptable, but this does not apply to liquid drugs due to pH concerns.

  • Container Sizes to be Tested: When a product is marketed in multiple container sizes, stability testing should include the smallest container size as it is considered the most critical in terms of container properties affecting product degradation. While testing all container sizes is recommended, not testing all sizes may not necessarily violate CGMP regulations.

  • Preservatives: Products formulated with preservatives should be monitored throughout their shelf life to ensure the effectiveness of the preservative system. Once a minimal effective level of preservative is established, chemical testing for the preservative(s) can be performed. The preservative system should be monitored at the same intervals as other ingredients.

  • Bulk Drug Substances: While expiration dating is not explicitly required for bulk drug substances in CG.

What Are ICH Guidelines for Shelf Life of Pharmaceuticals?

The international council for harmonization of technical requirements for pharmaceuticals for human use (ICH) provides guidelines on determining the shelf life of pharmaceuticals. These guidelines are outlined in the ICH Q1E evaluation of stability data.

Pharmaceutical drugs naturally undergo degradation over time, leading to the formation of potentially harmful by-products. The ICH Q1E guideline includes an estimate of the shelf life of pharmaceutical substances and products. The determination of shelf life involves a comprehensive evaluation of stability data, allowing for an informed decision on the appropriate timeframe for product consumption.

ICH Guidelines

1. In order to determine the estimated shelf life of a pharmaceutical product, the ICH Q1E guideline recommends using statistical modeling and linear or nonlinear regression through "pool ability" tests. This involves obtaining test results from at least three stability registration batches at predetermined storage times.

2. The analysis follows a stepwise approach to determine the most appropriate regression model for characterizing the response of the batches over storage time and estimating the shelf life. These regression models include common intercept and common slope, separate intercepts and common slope, or separate intercepts and separate slopes. Additionally, a simple linear regression model with a common intercept and varying slopes among batches is considered in practice.

3. The ICH guidelines adopt a fixed-batch approach for estimating shelf life. This ensures that the batches used in the stability study represent the entire distribution of the product in terms of its manufacturing process.

4. The registration batches included in the study originate from a manufacturing process that is under control. This is the underlying assumption in a stability study. The regression model with a common intercept and common slope is considered the most meaningful model to describe the mean response of a controlled process.

5. Estimating the common intercept and slope utilizes all available data from the stability study to provide the most precise estimate of the overall mean response over time. However, following the ICH strategy may not frequently select this model because increasing the precision of the estimates of intercept and slope increases the likelihood of detecting small differences among batches, even if they are inconsequential.

6. Consequently, the statistical calculations tend to favor regression models allowing for differing intercepts and/or slopes among batches. In these models, the estimated product shelf life is determined by the shortest estimate among the individual batches based on the ICH guidelines. This approach often results in an estimate biased towards a shorter storage time, relying heavily on data from the "worst-case" batch, which contradicts statistical principles.

7. In order to establish a storage time during which the product remains acceptable for all future batches manufactured, packaged, and stored under similar circumstances the ICH guidelines are formed. However, the statistical methodology recommended in the guidance document is incompatible with this intention.

8. Regardless of the regression model used, the estimated shelf life based on the ICH methods applies only to the batches used in the stability study, as the variation among batches is not estimated.

9. Inference to future batches of the pharmaceutical product requires information about batch-to-batch performance, which necessitates estimating the variation among batches. Extending the ICH Q1E methodology to treat stability study batches as a random sample from the entire production of the product still presents challenges in estimating the batch shelf lives and tends to underestimate the shelf life due to the continuous and nonnegative nature of the distribution of true batch shelf lives.

10. The true product shelf life can be alternatively defined as a quantile of the distribution of true batch shelf lives corresponding to the mean of the product distribution. However, this approach presents a limitation where, by the time the true product shelf life is reached, half of the product will have already exceeded the acceptance criteria.

Alternative Method:

An alternative strategy is proposed by the Working Group to estimate the true product shelf life, which aligns more closely with the philosophy and intent of the ICH definition. This alternative approach assumes that the batches included in the stability study are a random sample from the production process while using the same definition of true batch shelf life as the ICH approach for determining the labeled shelf life. This alternative strategy offers several advantages:

1. It allows for the estimation of among-batch variation separately from within-batch variation.

2. It provides the necessary information for making inferences about future batches of the pharmaceutical product.

3. It avoids the need for "pool ability" testing encountered in a fixed-batch analysis.

4. It overcomes the issue of estimating the true product shelf life based on data from the "worst-case" batch.

5. By adopting the random-batch model, the counterintuitive idea that including more batches in the stability, study leads to a shorter estimate of the true product shelf life is eliminated.

6. Instead, manufacturers are encouraged to include additional batches in the stability trial to obtain a more precise and accurate estimate of the true product shelf life.

7. The random-batch model utilizes the same samples and measurements as the ICH approach, but it differs in the estimation methodology.

Conclusion:

The random variation that needs to be understood in true batch shelf lives is crucial for comprehending the true product shelf life. With the goal of ICH Q1A in mind, the key question is how to interpret the statement that "drug product batches are expected to remain within specification." This question pertains to a characteristic of product distribution and its relationship to a corresponding characteristic of the distribution of true batch shelf lives. Therefore, the true product shelf life is defined as the characteristic of the distribution of true batch shelf lives that provides operational meaning to Q1A.